Fulcrum Therapeutics

Open enrollment with an early-phase pipeline tilt

According to ClinicalTrials.gov-derived indexes, Fulcrum Therapeutics sits in the upper quartile of US sponsors by registered trial count (#1,604 of 15,742 sponsors by registered trial count).

8 total trials 1 currently recruiting 4 completed early-phase tilt upper quartile by trial count

Fulcrum Therapeutics: 8 sponsored US clinical trials, 1 recruiting.

Fulcrum Therapeutics sponsors 8 registered US clinical trials on ClinicalTrials.gov, 1 of them currently recruiting, and 4 completed. 2 of these trials are in Phase 3-4 (later-stage) and 6 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Sickle Cell Disease, with 1 trials.

Upper-quartile sponsor footprint

Fulcrum Therapeutics sits in the upper quartile of the sponsor corpus (#1,604 of 15,742 sponsors by registered trial count) - denser than most sponsors, still short of the top-decile hubs.

Open and recent trials

8 total, page 1 of 1

RECRUITING Phase 1

Single-dose Pharmacokinetics of Pociredir in Participants With Sickle Cell Disease

NCT07431398
TERMINATED Phase 3

Efficacy and Safety of Losmapimod in Treating Participants With Facioscapulohumeral Muscular Dystrophy (FSHD) (REACH)

NCT05397470
COMPLETED Phase 1

Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Pociredir

NCT05169580
COMPLETED Phase 1

Relative Bioavailability and Food Effect Study of Losmapimod 15 mg Tablets

NCT05002231
COMPLETED Phase 1

Safety, Tolerability and Pharmacokinetics of FTX-6058

NCT04586985
TERMINATED Phase 3

Losmapimod Safety and Efficacy in COVID-19

NCT04511819
TERMINATED Phase 2

Efficacy and Safety of Losmapimod in Treating Subjects With Facioscapulohumeral Muscular Dystrophy (FSHD) With Open-Label Extension (OLE)

NCT04264442
COMPLETED Phase 2

Efficacy and Safety of Losmapimod in Subjects With Facioscapulohumeral Muscular Dystrophy (FSHD)

NCT04003974

Phase Distribution

PhaseTrial count
Phase 1 4
Phase 2 2
Phase 3 2

Therapeutic Areas

Sickle Cell Disease 1

What is open in the Fulcrum Therapeutics pipeline

1 recruiting of 8 indexed (13% open); 4 completed (50%).

Phase mix: 2 late (III/IV) vs 6 early (I/II) (early-phase heavy).

Top condition: Sickle Cell Disease (1 trial), 0 others listed.

How open-pipeline share is computed

Recruiting share is recruiting_count divided by trial_count for this sponsor in the public registry export. Status can change between pulls; treat the figure as a research-attention snapshot, not product availability.

Fulcrum Therapeutics: open-pipeline peers nationwide

Peers matched on 8 registered trials and 13% open enrollment, not the therapeutic-area sidebar.

Fulcrum Therapeutics sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together. Source: ClinicalTrials.gov (2026-08-08 snapshot). 2×2 strategic matrix plotting 9 entities by Total trials (X) and Recruiting share (Y), with a crosshair dividing the plot into four quadrants. Higher volume & more openFocused & more openHigher volume, mostly closedSmaller & mostly closed 681012141618 0%10%20%30%40% Total trials Recruiting share Fulcrum TherapeuticsAB ScienceAbbott Point of CareAbeona TherapeuticsAcademisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)Addario Lung Cancer Medical InstituteAmerican UniversityAnnexonAnsun Biopharma
Fulcrum Therapeutics sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together. Source: ClinicalTrials.gov (2026-08-08 snapshot).

Fulcrum Therapeutics sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.

Sponsors near 8 trials (± recruiting share)

Sponsors near 13% open enrollment (± trial volume)

Related

Read our methodology - how this data is sourced, computed, and verified.

What to do with this Fulcrum Therapeutics page

8 registered trials is a research-attention snapshot, not an endorsement of Fulcrum Therapeutics or any single study.

  • 1 of Fulcrum Therapeutics's trials are currently recruiting, check each one's own eligibility criteria before contacting a site. Browse recruiting trials
  • Sickle Cell Disease is the condition Fulcrum Therapeutics studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Sickle Cell Disease trials
  • Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide

Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.

Fulcrum Therapeutics pipeline card: 8 registered trials from official public datasets.Report a data error.